These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31799340)

  • 1. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend.
    Deal CL; Mitlak BH; Wang Y; Fitzpatrick LA; Miller PD
    Bone Rep; 2019 Dec; 11():100230. PubMed ID: 31799340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
    Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK
    J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
    Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
    Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
    Greenspan SL; Fitzpatrick LA; Mitlak B; Wang Y; Harvey NC; Deal C; Cosman F; McClung M
    Menopause; 2020 Oct; 27(10):1137-1142. PubMed ID: 32665529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
    Cosman F; Hans D; Shevroja E; Wang Y; Mitlak B
    J Bone Miner Res; 2023 Apr; 38(4):464-470. PubMed ID: 36588166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
    Miller PD; Hattersley G; Lau E; Fitzpatrick LA; Harris AG; Williams GC; Hu MY; Riis BJ; Russo L; Christiansen C
    Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
    Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
    J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).
    Winzenrieth R; Kostenuik P; Boxberger J; Wang Y; Humbert L
    JBMR Plus; 2022 Apr; 6(4):e10612. PubMed ID: 35434451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
    Czerwinski E; Cardona J; Plebanski R; Recknor C; Vokes T; Saag KG; Binkley N; Lewiecki EM; Adachi J; Knychas D; Kendler D; Orwoll E; Chen Y; Pearman L; Li YH; Mitlak B
    J Bone Miner Res; 2022 Dec; 37(12):2435-2442. PubMed ID: 36190391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
    Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
    Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
    Dhaliwal R; Hans D; Hattersley G; Mitlak B; Fitzpatrick LA; Wang Y; Schwartz AV; Miller PD; Josse RG
    JBMR Plus; 2020 Apr; 4(4):e10346. PubMed ID: 32258965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.